Status:
COMPLETED
Dietary Intervention in ADPKD on Tolvaptan
Lead Sponsor:
McMaster University
Conditions:
Polyuria
Autosomal Dominant Polycystic Kidney
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder. Tolvaptan has been approved in Canada as a treatment for ADPKD. Tolvaptan is an arginine vasopressin r...
Detailed Description
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder affecting 12.5 million persons worldwide, and impacting approximately 35,000-66,000 Canadians. An estim...
Eligibility Criteria
Inclusion
- Patients seen in the Hamilton Nephrology Genetics Clinic with a diagnosis of ADPKD taking tolvaptan
- Able to provide informed consent
- On maximal tolerated dose of tolvaptan for at least 3 months
Exclusion
- Serum sodium \> 135 mmol/L
- Patients with evidence of non-compliance (not completing monthly blood work required while on tolvaptan therapy).
- Unlikely to continue in Hamilton Nephrology Genetics Clinic for at least 6 months (planned dialysis initiation, transplant)
Key Trial Info
Start Date :
June 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 16 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT03858439
Start Date
June 6 2019
End Date
May 16 2022
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Joseph's Healthcare
Hamilton, Ontario, Canada, L8N 4A6